Implementing anti-retroviral therapy in resource-constrained settings: a randomized controlled trial to assess the effect of integrated tuberculosis and HIV care on the incidence of AIDS-defining conditions or mortality in subjects co-infected with tuberculosis and HIV
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Antituberculars; Didanosine; Efavirenz; Isoniazid/rifampicin; Lamivudine; Rifampicin/isoniazid/pyrazinamide/ethambutol
- Indications HIV infections; Pulmonary tuberculosis
- Focus Therapeutic Use
- Acronyms START
- 23 Nov 2011 Results of the pharmacokinetic sub-study published in the European Journal of Clinical Pharmacology.
- 30 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Mar 2010 Biomarkers information updated